Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 2/20 | 0.63 |
| ▸ | IL1RN | P18510 | 1/20 | 0.62 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.62 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.60 |
| ▸ | CCKAR | P32238 | 1/20 | 0.60 |
| ▸ | CCKBR | P32239 | 1/20 | 0.60 |
| ▸ | ECE1 | P42892 | 6/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.57 |
| ▸ | MME | P08473 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29199429 | 0.89 | ERAP2 (0.68) | ACEIL1RNERAP2OPRD1ECE1 | |
| SCHEMBL29199418 | 0.89 | ERAP2 (0.68) | ACEIL1RNERAP2OPRD1ECE1 | |
| SCHEMBL29993798 | 0.89 | OPRD1 (0.65) | ACEIL1RNERAP2OPRD1CCKAR | |
| SCHEMBL28544120 | 0.88 | IL1RN (0.64) | ACEIL1RNERAP2OPRD1CCKAR | |
| SCHEMBL28544119 | 0.88 | IL1RN (0.64) | ACEIL1RNERAP2OPRD1CCKAR | |
| SCHEMBL27893082 | 0.87 | ACE (0.64) | ACEIL1RNERAP2OPRD1CCKAR | |
| SCHEMBL29577668 | 0.86 | ERAP1 (0.68) | IL1RNERAP2OPRD1OPRM1 | |
| SCHEMBL30010730 | 0.86 | ERAP1 (0.66) | IL1RNERAP2OPRD1OPRM1 | |
| SCHEMBL30011658 | 0.86 | ERAP1 (0.66) | IL1RNERAP2OPRD1OPRM1 | |
| SCHEMBL29577129 | 0.86 | ERAP1 (0.68) | IL1RNERAP2OPRD1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220047679-A1 | COMBINATION THERAPY | ANTISENSE THERAPEUTICS LTD (AU) | 2022-02-17 | — | — | US | claimed |
| US-20220047679-A1 | COMBINATION THERAPY | ANTISENSE THERAPEUTICS LTD (AU) | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220047679-A1 | COMBINATION THERAPY | GHSR, GHRHR, IGF1R | ACE 2117/4885IL1RN 239/4885ERAP2 731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.